CompletedNCT01234779

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Little Rock and 45 more locationsSee all locations and recruitment
Study phase: Phase 2

Study clarity

Study start dateFebruary 2011

Recruitment status: Completed
Enrollment listed in the registry: 301
Sponsor: Hoffmann-La Roche
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, Romania, Russia, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT01234779
Official title: Show the full official title
A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia

Completed

Little Rock, United States · Cerritos, United States · Oceanside, United States

37 more locations

FAQ

Who is behind this study?

The study sponsor is Hoffmann-La Roche.

Did this study involve medication?

Yes. The study involved medication, including bitopertin [RO4917838], olanzapine and placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.